News Releases

Date Title
04/16/2016 Summary ToggleEnanta Announces New Data from AbbVie’s SURVEYOR-1 and SURVEYOR-2 Studies Showing High Sustained Virologic Response Rates after 8 or 12 Weeks of Treatment in Patients with any of Genotypes 1 through 6 of Hepatitis C Virus
04/15/2016 Summary ToggleEnanta Announces that AbbVie’s Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
04/14/2016 Summary ToggleEnanta Announces High SVR Rates with AbbVie’s VIEKIRAX® + EXVIERA® Regardless of the Presence of Resistance-Associated Variants Prior to Treatment in Genotype 1 Chronic Hepatitis C Patients
03/30/2016 Summary ToggleEnanta Pharmaceuticals Announces HCV Data Presentations at The International Liver Congress™ 2016
03/10/2016 Summary ToggleEnanta Pharmaceuticals to Present at the Barclays Global Healthcare Conference
02/26/2016 Summary ToggleEnanta Pharmaceuticals Announces CHMP Positive Opinion for AbbVie’s VIEKIRAX® + EXVIERA® Without Ribavirin for the Treatment of Chronic Hepatitis C in Genotype 1b Patients with Compensated Cirrhosis
02/08/2016 Summary ToggleEnanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015
02/01/2016 Summary ToggleEnanta Pharmaceuticals to Present at the LEERINK Partners 5th Annual Global Healthcare Conference
01/28/2016 Summary ToggleEnanta Pharmaceuticals to Host Conference Call on February 8 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal First Quarter Ended December 31, 2015
01/11/2016 Summary ToggleEnanta Pharmaceuticals Announces New R&D Initiatives in Hepatitis B Virus and Respiratory Syncytial Virus and Plan to Provide Data Updates on Programs in NASH and HCV at the 34th Annual J.P. Morgan Healthcare Conference